Skip to Content
Merck
CN
  • Modelling of pancreatic cancer biology: transcriptomic signature for 3D PDX-derived organoids and primary cell line organoid development.

Modelling of pancreatic cancer biology: transcriptomic signature for 3D PDX-derived organoids and primary cell line organoid development.

Scientific reports (2020-02-19)
Shannon R Nelson, Chenxi Zhang, Sandra Roche, Fiona O'Neill, Niall Swan, Yonglun Luo, AnneMarie Larkin, John Crown, Naomi Walsh
ABSTRACT

With a five-year survival rate of 9%, pancreatic ductal adenocarcinoma (PDAC) is the deadliest of all cancers. The rapid mortality makes PDAC difficult to research, and inspires a resolve to create reliable, tractable cellular models for preclinical cancer research. Organoids are increasingly used to model PDAC as they maintain the differentiation status, molecular and genomic signatures of the original tumour. In this paper, we present novel methodologies and experimental approaches to develop PDAC organoids from PDX tumours, and the simultaneous development of matched primary cell lines. Moreover, we also present a method of recapitulating primary cell line cultures to organoids (CLOs). We highlight the usefulness of CLOs as PDAC organoid models, as they maintain similar transcriptomic signatures as their matched patient-derived organoids and patient derived xenografts (PDX)s. These models provide a manageable, expandable in vitro resource for downstream applications such as high throughput screening, functional genomics, and tumour microenvironment studies.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
ECM Gel from Engelbreth-Holm-Swarm murine sarcoma, liquid, BioReagent, suitable for cell culture
Sigma-Aldrich
TWEEN® 20, viscous liquid
Sigma-Aldrich
ECO TWEEN® 20, viscous liquid